Attached files
| file | filename |
|---|---|
| 8-K - 8-K - PIERIS PHARMACEUTICALS, INC. | form8-k.htm |
Jefferies Global Healthcare Conference Presentation June 2018 (Nasdaq: PIRS)
Forward Looking Statements This press release contains forward-looking statements as that term is defined in Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. Statements in this press release that are not purely historical are forward-looking statements. Such forward-looking statements include, among other things, references to novel technologies and methods and our business and product development plans, including the advancement of our proprietary and co-development programs into and through the clinic. Actual results could differ from those projected in any forward-looking statements due to numerous factors. Such factors include, among others, our ability to raise the additional funding we will need to continue to pursue our business and product development plans; the inherent uncertainties associated with developing new products or technologies and operating as a development stage company; our ability to develop, complete clinical trials for, obtain approvals for and commercialize any of our product candidates, including our ability to recruit and enroll patients in our studies; our ability to address the requests of the FDA; competition in the industry in which we operate and market conditions. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements, except as required by law. Investors should consult all of the information set forth herein and should also refer to the risk factor disclosure set forth in the reports and other documents we file with the SEC available at www.sec.gov, including without limitation the Company's Annual Report on Form 10-K for the fiscal year ended December 31, 2017 and the Company's Quarterly Reports on Form 10-Q. 2
Anticalin Proteins: A Novel Therapeutic Class Features Benefits Derived from lipocalins No observed (human epithelial proteins) immunogenicity to date Engineerable binding pocket Potent target engagement Unique bi/multispecific fusion Engineerable scaffold proteins Enhanced delivery, e.g., Small size (1/8th the size of a mAb) Inhaled therapeutics Our pipeline addresses clinically-validated targets in new ways by leveraging unique features of the Anticalin® protein drug class, effectively taking reduced target biology risk 3
Pieris Investment Opportunity • An industry-validated class of novel therapeutics - Anticalin proteins - $120+M in upfront payments and milestones since January 2017 • Potentially transformative, wholly owned IO program Immuno-oncology - Clinical-stage, tumor-targeted 4-1BB bispecific • High-value, inhaled targeted respiratory program - Clinical-stage inhaled IL-4Ra antagonist - partnered with AstraZeneca – retained co-dev/US comm rights • All three anchor partnerships include US-focused commercialization rights • Robust IND engine that has yielded several clinical-stage Respiratory candidates with excellent drug-like properties ANCHOR PARTNERSHIPS 4
Financial Update (3/31/18) 2018 Anticipated Milestones (in millions) • PRS-343: Initial safety and PD data; initiate PDL-1 Cash & Cash Equivalents (proforma) $162.2 Core Clinical combo study in 2H18 • PRS-060: First-in-human data in 2H18 Debt $0.0 Non-Core • PRS-080: Phase IIa data in 2H18 (safety, PK, Clinical hemoglobin change post 5QW dosing) 2017 Opex $39.3 Next-Generation • Advance multiple programs in immuno-oncology and CSO 50.1 Pipeline respiratory Pipeline Highlights DISCOVERY PRECLINICAL PHASE I PHASE II PRS-080 PRS-343 PRS-060 Servier PRS-300’s AZ SeaGen Two IO INDs Planned in 2019 Advance additional respiratory programs under the AstraZeneca alliance in 2018 5
Anticalin Proteins: A Novel Therapeutic Class Features Benefits Derived from lipocalins No observed (human epithelial proteins) immunogenicity to date Engineerable binding pocket Potent target engagement Unique bi/multispecific fusion Engineerable scaffold proteins Enhanced delivery, e.g., Small size (1/8th the size of a mAb) Inhaled therapeutics Our pipeline addresses clinically-validated targets in new ways by leveraging unique features of the Anticalin® protein drug class, effectively taking reduced target biology risk 6
4-1BB (CD137): Validated Target in Need of Appropriate Drug • Marker for tumor-specific T cells in TME • Drives anti-tumor cytolytic activity • Ameliorates T cell exhaustion & critical for T cell expansion • Drives central memory T cell phenotype Systemically agonizing 4-1BB mAb (urelumab) has shown clinical activity yet caused significant toxicity HER2+ Tumor Cell HER2-Targeting Antibody PRS-343 Tumor-Specific T-cell 4-1BB-Targeting Anticalin Proteins PRS-343 was designed for TME-specific 4-1BB activation* *4-1BB trimerization required for activation 7
Anticalin Platform: Well-Equipped for Targeted IO Agonism A Varied Immune Synapse... ... Does Not Materially Impact Target Engagement... ...But Impacts Efficacy The Natural Immune Synapse TNFRSL ~15nm (e.g. 4-1BB Ligand) 13.4 nm C-terminal Heavy chain fusion TNFRS (e.g. 4-1BB) ~8nm C-terminal Light chain fusion Efficacy Experimental Design IFN-g IL-2 ~5nm Activation 4-1BB/HER-2 T Cell bispecific N-terminal Heavy chain fusion Signal 1 Signal 2 4-1BB HER-2 ~5nm a-CD3 a-CD3 Antibody antibody Culture Dish HER-2+ N-terminal Light chain fusion Tumor Cell Stand-alone Bispecific-based 8 building block affinity building block affinity
PRS-343 Shows Localized Activity in Humanized Mouse Model CD8+ Proliferation in TME Peripheral CD8+ Proliferation Systemic Toxicity PRS-343 Yes No No 4-1BB mAb No Yes Yes Isotype Control No No No CD8+ Proliferation in TME Peripheral CD8+ Proliferation Systemic Toxicity hCD3 hCD4 hCD8 Plot 100μg PRS-343 100 CD3 CD4 CD8 100μg anti-4-1BB 30 CD45 100µg 20 PRS-343 + mAb 10 % CD8 Frequency [%] 0 of 100μ IgG4 isotype + 30 CD45 CD3 CD4 CD8 ctrl CD45 50 100µg 20 Isotype Ctrl 10 Frequency [%] 0 Percent Survival 30 CD3 CD4 CD8 CD45 100µg 20 Anti-4-1BB 10 Frequency [%] 0 0 10 20 30 40 Experimental design: SKOV-3 tumor cells grafted onto immune- deficient mice; human PBLs + control or PBLs + PRS-343 administered once grafted tumor reaches predetermined volume 9
PRS-343 Phase 1 Enrollment* Cohorts 1-4 Cohort 5 (predicted minimally active dose) Cohort 6 Cohort 7 2H18 Cohort 8 (screening ongoing) screening Cohorts 9-11 to be enrolled ongoing 2H18: Initiating PD-L1 combo trial n = 3 n = 5 n = 2 2H18 n = 5 Sept ‘17 - Feb ‘18 Mar ‘18 Apr ‘18 May ‘18 Jun ‘18 Jul ‘18 ** ** *Enrollment status as of 6/6 **Site initiation planned 10
PRS-343 Patient Recruitment Strategy for Escalation and Expansion ESCALATION EXPANSION HER2+ all-comers to efficiently interrogate therapeutic window during escalation Tumor types enrolled to date*: Bladder Breast Cholangiocarcinoma Colorectal adenocarcinoma Endometrial Esophageal Gastric Gastric GEJ adenocarcinoma Pancreatic Vulvar carcinoma Other(s) Similar strategy to be employed for Tecentriq® combination trial *Enrollment status as of 6/6 11
Immuno-oncology Franchise Prioritizing PRS-343 “fast-followers” and diversified costim agonism beyond 4-1BB Proprietary Clinical (worldwide rights) • PRS-343: First-in-class bispecific to preferentially activate T cells in the tumor microenvironment (TME) • Committed to advancing several additional tumor-localized costimulatory bispecific fusion proteins Servier Alliance • 5-program deal (all bispecific fusion proteins) • Pieris retains full U.S. rights for 3 out of 5 programs • $31M upfront payment, $1.8B milestone potential • Up to low double-digit royalties on non-codev products Seattle Genetics Collaboration • 3-program partnership based on tumor-localized costimulatory bispecific fusion proteins • Pieris retains opt-in rights for 50/50 global profit split and US commercialization rights on one of the programs • $30 upfront payment, $1.2B milestone potential • Up to double-digit royalties on non-codev products 12
Anticalin Proteins: A Novel Therapeutic Class Features Benefits Derived from lipocalins No observed (human epithelial proteins) immunogenicity to date Engineerable binding pocket Potent target engagement Unique bi/multispecific fusion Engineerable scaffold proteins Enhanced delivery, e.g., Small size (1/8th the size of a mAb) Inhaled therapeutics Our pipeline addresses clinically-validated targets in new ways by leveraging unique features of the Anticalin® protein drug class, effectively taking reduced target biology risk 13
PRS-060 is an Inhaled Drug Candidate for Uncontrolled Asthma Why did we design this? What We Know Regeneron/Sanofi’s dupilumab (systemically administered anti-IL-4Ra antibody) has demonstrated the following: Reduction in biomarker (FeNO) Improved lung function Exacerbation Reduction & Steroid Sparing 67% 80% reduction in avg. reduction high-eosinophil in corticosteroid patients use What We Are Testing • Is this a local phenomenon? • First-in-man study underway via inhaled delivery 14
Preclinical In Vivo PoC Support Clinical Development • First inhaled Anticalin protein to potently engage the highly validated asthma target, IL-4Ra • Localized target engagement in lung tissue supports a rationale for a convenient, low-dose, low-cost alternative to systemically administered antibodies • Preclinical in vivo PoC for pulmonary delivery at doses supportive of daily administration Lung Total and differential cell counts in OVA model Histopathology hIL-13-induced increases in eotaxin Control 48-hr gene expression P ercentage inhibition of lung inflam m atory cells 6 × 10 06 48hr after OVA challenge 1 .5 Percentage inhibition 78% 71% 79% 66% 5 × 10 06 97% 86% 73% 58% 47% 1 .0 ** 4 × 10 06 × 06 3 10 *** 0 .5 expression 2 × 10 06 *** Cell differential ** ** PRS-060 48-hr *** 06 *** 1 × 10 eotaxin Change in Fold ** 0 .0 * 0 hIL-13 T otal M acrophages Eosinophils Lymphocytes Treat: Veh 50µ g 2µ g 48hr timepoint Pre (hr): 0.5 4 8 24 Anticaln control *p<0.05, **p<0.001 compared with control TLPC134, (TLPC134) ** p<0.01, ***p<0.001 compared to anticalin control, unpaired two-tailed t test (n=9-10); data are Mean± SEM PRS-060 unpaired two-tailed t-test (n=5-6); data are Mean ± SEM Inhibits the influx of key inflammatory cells 24-hr duration of action at doses both in lavage fluid and lung tissue feasible for inhalation 15
AstraZeneca Provides Complementary Development Know-how • PRS-060 (Part of AstraZeneca alliance) - First-in-class inhaled IL-4Ra antagonist for asthma - Phase1a SAD initiated in 4Q17 Alliance Highlights - Pieris retains opt-in for co-development/co-commercialization rights in the US • Proprietary inhaled discovery programs ongoing 5 committed novel inhaled Anticalin protein programs Including lead asthma program PRS-060 (IL-4Ra) Retained co-development and co-commercialization (US) options on PRS-060 and up to 2 additional programs $57.5M upfront & Phase I MS in 2017; up to ~$2.1B in milestones, plus double-digit royalties Access to complementary formulation and device know-how for inhaled delivery 16
Pieris Pharmaceuticals, Inc. Corporate HQ: 255 State Street, 9th Floor, Boston, MA 02109, USA R&D Hub: Freising, Germany (Munich) info@pieris.com www.pieris.com
Appendix
PRS-080 Shows Consistent Effects in Healthy Volunteers & CKD5 Patients – Ongoing Ph IIa Study will Evaluate Hemoglobin • In both healthy volunteers and CKD5 patients, Ph I SAD in Healthy Volunteers* Ph Ib SAD in CKD5 patients** PRS-080 Mean Iron Concentrations† Mean Iron Concentrations 60 60 Was safe and well-tolerated o 50 50 o Showed a dose-proportional increase of PK 40 40 parameters (data not shown) 30 30 Serum Iron [µM] o Demonstrated dose-dependent PD effects on 20 Serum Iron [µM] 20 serum iron and TSAT 10 10 o Led to an immediate dose-dependent decrease 0 0 in circulating free hepcidin (data not shown) 0 48 96 144 192 240 0 48 96 144 • A Phase IIa trial is underway in Germany and Mean TSAT (%)† Mean TSAT (%) Czech Republic 100 100 80 80 • Planning 5 QW infusions in ESRD FID anemia patients 60 60 40 • Two dose cohorts: 4 mg/kg and 8 mg/kg body TSAT (%) TSAT (%) 40 weight (4 drug; 2 placebo per cohort) 20 20 • Safety, tolerability hemoglobin (Hb) and 0 0 reticulocyte concentration of Hb as endpoints 0 48 96 144 192 240 0 48 96 144 Time after start of infusion [hours] Time after start of infusion [hours] • Presented at 57th ASH Conference December 2015 ** Presented at 54th ERA-EDTA Conference June 2017 • If data are positive, Pieris will seek to out- † Subjects achieving iron response > 34.5 µM N=24 (6 patients per dose cohort, 6 patients on placebo) license beyond Japan (avg. 3 out of 6 subjects / dose cohort) 19
Management and Board Executive Management Team Stephen Yoder, J.D. Louis Matis, M.D. Allan Reine, M.D. President & CEO SVP, Chief Development Officer SVP, Chief Financial Officer CGI Pharmaceuticals Board of Directors Julian Adams, Ph.D. Jean-Pierre Bizzari, M.D. Christopher Kiritsy Michael Richman President & CEO, Gamida Cell Director CEO, Arisaph Pharmaceuticals CEO, NextCure Clal BioTech Industries,Ltd., Infinity, Celgene, Servier, Rhone-Poulenc, Kos Pharmaceuticals Amplimune, Chiron, MedImmune, Millennium Pharm., LeukoSite Inc. Sanofi-Aventis Macrogenics Ann Barbier, M.D., Ph.D. James Geraghty Steven Prelack Stephen Yoder CMO, Translate Bio Director SVP & COO, VetCor President & CEO Third Rock Ventures, Sanofi, Genzyme, Bain Aerpio, Galectin Therapeutics, BioVex and Company Group 20